AOD-9604 is a synthetic peptide fragment of human growth hormone (hGH) comprising residues 176-191. It was developed to replicate the fat-metabolizing benefits of hGH without the adverse effects associated with IGF-1 elevation. Preclinical studies in rodents demonstrated significant reductions in adiposity without compromising insulin sensitivity. Human clinical trials (up to 1 mg/day) indicated excellent safety profiles but limited efficacy in producing significant weight loss, leading to discontinued development in 2007. However, renewed interest has emerged around higher-dose investigational formulations such as the 5 mg AOD-9604 offered by Kimera Chems, prompting a re-evaluation of its biological and clinical relevance.
What is AOD-9604?
Obesity remains a critical global health issue, with strong correlations to type 2 diabetes, cardiovascular disease, musculoskeletal disorders, and reduced life expectancy. Despite significant therapeutic advancements, challenges with long-term safety, tolerability, and patient adherence persist.
Peptides such as AOD-9604 have emerged as potential alternatives for managing obesity and metabolic dysfunction due to their specificity and reduced side-effect profiles. As a C-terminal fragment of hGH, AOD-9604 was engineered to induce fat metabolism without the mitogenic effects of full-length GH.
Mechanism of action
AOD-9604 mimics the lipolytic region of hGH, primarily influencing fat metabolism via β3-adrenergic receptors on adipocytes. It promotes lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without increasing IGF-1 levels, a key differentiator from full-length GH. This selective action is attributed to its 16-amino acid sequence (Tyr-hGH(176–191)).
Rodent studies confirmed that AOD-9604 enhances lipid oxidation and energy expenditure. Knockout models lacking β3-adrenergic receptors showed diminished response, supporting the receptor-specific mechanism.
Preclinical evidence
In obese Zucker rats, daily administration of AOD-9604 (500 µg/kg) over 19 days significantly reduced weight gain compared to controls. Importantly, insulin sensitivity was preserved, unlike in full GH-treated animals, which often experience insulin resistance.
Chronic exposure studies in rats and monkeys revealed no adverse genotoxic effects. AOD-9604 did not produce organ toxicity in 6- to 9-month toxicology studies and was well-tolerated across species. Notably, it did not stimulate IGF-1 or affect glucose homeostasis.
These findings provided a foundation for human trials, which explored daily doses up to 1 mg; well below the 5 mg experimental formulation later developed for research purposes.
Clinical trials in humans
Six Phase I/II clinical studies (total n ≈ 900) assessed various administration routes (oral, IV, subcutaneous) with doses ranging from micrograms to 1 mg/day. Across all trials:
- No serious adverse events occurred.
- No immunogenic responses were reported.
- Glucose and insulin levels remained stable.
- No changes in IGF-1 or hormonal profiles were detected.
These results positioned AOD-9604 as a biologically safe peptide.
The most promising result came from a 12-week randomized, double-blind, placebo-controlled study where 1 mg/day AOD-9604 led to approximately 2.6 kg weight loss vs. 0.8 kg in the placebo group. However, extended trials failed to replicate significant weight loss benefits. Consequently, the sponsor halted its clinical development in 2007.
Despite its strong safety profile, the observed efficacy was deemed clinically insufficient to continue formal drug development under current guidelines.
Revisiting AOD-9604 at 5 mg: the Kimera Chems product
As of 2025, Kimera Chems offers a 5 mg formulation of AOD-9604 for laboratory and research purposes (Kimera Chems – AOD-9604 5mg). According to the product page:
- The peptide is intended strictly for research use.
- It comes as lyophilised powder requiring reconstitution.
- Purity is ≥99%, verified via analytical methods.
- No claims are made regarding human efficacy or medical treatment.
This product reignited interest in the dose–response curve of AOD-9604. Since human studies have not exceeded 1 mg/day, the 5 mg dose remains unexplored in clinical settings, though it offers a viable starting point for preclinical dose escalation studies.
Important caution: The 5 mg dose should not be assumed to be safe or efficacious in humans without appropriate trials. Researchers using this product are strongly advised to adhere to ethical and regulatory boundaries, as explicitly stated by Kimera Chems.
Expanded applications
Recent animal studies suggest AOD-9604 may promote cartilage repair by increasing proteoglycan and collagen synthesis in chondrocytes. In rabbit models, intra-articular injections showed reduced cartilage degeneration; especially when combined with hyaluronic acid.
Stem cell studies indicated AOD-9604 may enhance the differentiation of mesenchymal stem cells into osteoblasts, offering potential utility in osteoporosis or skeletal trauma recovery.
Preliminary in vitro experiments show AOD-9604, when encapsulated with doxorubicin, may increase apoptotic signalling in breast cancer (MCF-7) cells an area needing deeper exploration.
These applications are distinct from its metabolic effects and may represent the compound’s most promising future roles.
What else you need to know?
Despite its excellent safety profile, AOD-9604’s clinical efficacy in treating obesity has been underwhelming at ≤1 mg/day. Biological adaptation, dose limitations, and insufficient mechanistic intensity likely hindered outcomes.
The 5 mg formulation, such as that from Kimera Chems, could overcome some limitations if shown to increase adipose targeting without systemic activation of IGF-1. However, this remains theoretical. Properly designed dose-escalation studies in humans are urgently required before any conclusions can be drawn.
Given the clean safety history at lower doses, 5 mg may be tolerable, but until confirmed, this remains speculation. Ethical use in regulated experimental settings is the only responsible path forward.
Takeaway
AOD-9604 remains a compelling compound with mechanistically unique lipolytic properties and a near-perfect safety profile at ≤1 mg/day in humans. However, its clinical effectiveness in weight loss remains limited, and no human trial has evaluated the potential of 5 mg dosing. The Kimera Chems formulation (AOD-9604 5mg) provides a research-grade compound to explore such possibilities under controlled laboratory conditions.
Future efforts should prioritize dose-escalation safety trials, mechanistic studies involving adipose-specific markers, and investigations into cartilage, bone, and regenerative applications. Only with rigorous data can AOD-9604 transition from investigational compound to viable therapy.
References
- Heffernan et al. (2000). Effects of GH fragment 176–191 on adiposity in Zucker rats. Journal of Endocrinology.
- AOD-9604 product page – Kimera Chems. Accessed August 2025.
- Wikipedia Contributors. AOD9604. Retrieved from Wikipedia.
- Regulatory Review. FDA GRAS Notification for AOD-9604. Downloads.regulations.gov.
- Elite Plastic Surgery Peptide Review. Cartilage effects of AOD-9604. eliteplasticsurgeryaz.com.
Adam Mulligan, a psychology graduate from the University of Hertfordshire, has a keen interest in the fields of mental health, wellness, and lifestyle.
